Icon (NASDAQ:ICLR) Earns “Buy” Rating from Mizuho

Share on StockTwits

Mizuho reaffirmed their buy rating on shares of Icon (NASDAQ:ICLR) in a research report report published on Thursday morning, The Fly reports. They currently have a $194.00 target price on the medical research company’s stock, up from their previous target price of $179.00.

A number of other equities analysts have also recently weighed in on ICLR. BidaskClub raised shares of Icon from a hold rating to a buy rating in a research report on Friday, January 17th. Zacks Investment Research cut shares of Icon from a buy rating to a hold rating in a research report on Wednesday, January 29th. Credit Suisse Group reissued a buy rating and set a $160.00 price target on shares of Icon in a research report on Monday, October 28th. SunTrust Banks cut shares of Icon from a buy rating to a hold rating and lifted their price target for the stock from $170.00 to $182.00 in a research report on Monday, January 27th. Finally, UBS Group set a $160.00 price target on shares of Icon and gave the stock a hold rating in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $180.11.

ICLR opened at $170.98 on Thursday. The company has a fifty day moving average price of $171.94 and a two-hundred day moving average price of $158.93. The firm has a market capitalization of $9.23 billion, a PE ratio of 25.14, a P/E/G ratio of 1.94 and a beta of 0.77. Icon has a 52 week low of $127.58 and a 52 week high of $178.99. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.03 and a current ratio of 2.03.

Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $1.83 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.83. The company had revenue of $725.40 million for the quarter, compared to analysts’ expectations of $734.13 million. Icon had a net margin of 13.33% and a return on equity of 25.00%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period last year, the firm posted $1.62 earnings per share. Equities analysts forecast that Icon will post 7.72 EPS for the current year.

A number of large investors have recently modified their holdings of the business. Financial Counselors Inc. increased its stake in shares of Icon by 1.2% during the 4th quarter. Financial Counselors Inc. now owns 5,183 shares of the medical research company’s stock worth $893,000 after purchasing an additional 60 shares during the last quarter. Creative Planning raised its holdings in Icon by 2.8% during the 4th quarter. Creative Planning now owns 2,345 shares of the medical research company’s stock valued at $404,000 after buying an additional 64 shares during the last quarter. FTB Advisors Inc. grew its position in shares of Icon by 27.6% in the 3rd quarter. FTB Advisors Inc. now owns 361 shares of the medical research company’s stock worth $52,000 after buying an additional 78 shares during the period. Cim LLC grew its position in shares of Icon by 1.6% in the 4th quarter. Cim LLC now owns 5,107 shares of the medical research company’s stock worth $880,000 after buying an additional 81 shares during the period. Finally, Shine Investment Advisory Services Inc. grew its position in shares of Icon by 10.7% in the 4th quarter. Shine Investment Advisory Services Inc. now owns 848 shares of the medical research company’s stock worth $146,000 after buying an additional 82 shares during the period. 84.92% of the stock is currently owned by hedge funds and other institutional investors.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Story: Percentage Gainers

The Fly

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.